(secondQuint)Homocysteine Lowering and Atherosclerosis Reduction Trial (HART).

 The HART study is designed as a substudy of the Heart Outcomes Prevention Evaluation-2 (HOPE-2)trial which evaluates the effect of combined therapy ? folic acid and vitamin B6 and B12 on clinical events.

 The study is designed to enrol 900 study participants randomized to homocysteine lowering therapies or placebo.

 Follow-up will estimate over 5 years.

 Study participants will undergo yearly carotid B-Mode ultrasound examinations.

.

 Homocysteine Lowering and Atherosclerosis Reduction Trial (HART)@highlight

Study Objective: 1.

 To evaluate whether combined therapy with folic acid 2.

5 mg/day, vitamin B6 50 mg/day and vitamin B12 1000 micrograms/day vs placebo reduces the rate of atherosclerosis progression, as evaluated by quantitative B-mode carotid ultrasound (US).

